Public-registry trials using FXS6837 Capsule that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH. | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Paroxysmal Nocturnal Hemoglobinuria | PHASE3 | 1 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
